Skip to content

Clinical trials

Frailty trials with no applicable phase

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Condition: Frailty Phase: Not applicable Clear all

664 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20053
20062
20086
20091
20103
20116
20123
20138
201416
201510
201613
201723
201841
201946
202050
202171
202260
202375
202474
202582
202668

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed313
Recruiting123
Unknown status109
Not yet recruiting60
Active, not recruiting23
Terminated15
Withdrawn14
Enrolling by invitation6
Suspended1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
The Hong Kong Polytechnic University11
Fundacion Miguel Servet10
The University of Hong Kong10
VA Office of Research and Development9
McGill University Health Centre/Research Institute of the McGill University Health Centre8
National Yang Ming Chiao Tung University8
National Taiwan University Hospital7
University Hospital, Toulouse7
Nova Scotia Health Authority6
University of Valencia6

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Frailty664
Sarcopenia89
Cognitive Dysfunction30
Heart Failure22
Malnutrition16
Neoplasms16
Cardiovascular Diseases14
Dementia14
Diabetes Mellitus11
Mobility Limitation11

Trials

Showing 51 to 75 of 664. Each trial links to its page on Pharma Observatory.

564 more trials match. See them on Pharma Observatory

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.